Cargando…

What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors?

Detalles Bibliográficos
Autores principales:	Bravaccini, Sara, Ulivi, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082295/ https://www.ncbi.nlm.nih.gov/pubmed/32206564 http://dx.doi.org/10.21037/tlcr.2019.12.06

Ejemplares similares

PD-1/PD-L1 inhibitors as a hope for smokers of non-small cell lung cancer patient
por: Yu, Zhuo, et al.
Publicado: (2019)

Response to ‘The effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors’
por: Ogale, S
Publicado: (2018)

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
por: Wu, Dawei, et al.
Publicado: (2022)

PD-1/PD-L1 expression is frequent and correlated with lymphocyte density in Erdheim-Chester disease
por: Charlotte, Fréderic, et al.
Publicado: (2022)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

A novel signature based on pairwise PD‐1/PD‐L1 signaling pathway genes for predicting the overall survival in patients with hepatocellular carcinoma
por: Zhao, Enfa, et al.
Publicado: (2021)

Pan‐cancer analysis revealing DAAM1 as a novel predictive biomarker for PD‐1/PD‐L1 blockade in clear cell renal cell carcinoma
por: Mei, Jie, et al.
Publicado: (2022)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Synchronous ground‐glass nodules showed limited response to anti‐PD‐1/PD‐L1 therapy in patients with advanced lung adenocarcinoma
por: Wu, Fengying, et al.
Publicado: (2020)

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
por: Italiano, Antoine, et al.
Publicado: (2020)

PD-L1 expression in regional lymph nodes and predictable roles in anti-cancer immune responses
por: Komohara, Yoshihiro, et al.
Publicado: (2020)

PD-L1 status and Immune checkpoint inhibitors in kidney cancer: ignorance, lack of knowledge or both
por: Tezval, Hossein, et al.
Publicado: (2021)

HTLV‐1 seropositive patients with lung cancer treated with PD‐1 inhibitors
por: Yoneshima, Yasuto, et al.
Publicado: (2020)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Nuclear AhR and membranous PD-L1 in predicting response of non-small cell lung cancer to PD-1 blockade
por: Han, Si-Chong, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
por: Zhang, Xuexia, et al.
Publicado: (2022)

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
por: Yang, Hui, et al.
Publicado: (2020)

Machine Learning for Predicting Hyperglycemic Cases Induced by PD-1/PD-L1 Inhibitors
por: Yang, Jincheng, et al.
Publicado: (2022)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

Identification of TMB, CD8 T‐cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit–toxicity ratio of anti‐PD‐1/PD‐L1 therapy
por: Long, Junyu, et al.
Publicado: (2021)

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model
por: Mu, Songlin, et al.
Publicado: (2022)

PD-L1 expression in pulmonary lymphoepithelioma-like carcinoma: is it a prognostic biomarker?
por: Li, Wen, et al.
Publicado: (2022)

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2021)

The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia
por: Ding, Xing-chen, et al.
Publicado: (2021)

Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation
por: Manson, Guillaume, et al.
Publicado: (2020)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
por: Martini, Dylan J., et al.
Publicado: (2017)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges
por: Yang, Fang, et al.
Publicado: (2021)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
por: Cheng, Chao, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors
por: Scognamiglio, Giosue, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k2t3eplha466emmdpau1r1lmde